Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Article
  • Published:

Angiogenesis is confined to the transient period of VEGF expression that follows adenoviral gene delivery to ischemic muscle

Abstract

Therapeutic angiogenesis involves the introduction of exogenous growth factor proteins and genes into ischemic tissues to augment endogenous factors and promote new vessel growth. Positive results from studies in animal models of peripheral arterial disease (PAD) and coronary artery disease over the past decade have supported the implementation of clinical trials testing vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) proteins and genes. Although several clinical trials reported positive results, others have been disappointing and results of a recent Phase II trial of VEGF delivered by adenovirus (the RAVE trial) were negative. It has been suggested that the duration of gene expression following delivery by adenovirus may be insufficient to produce stable vessels. Here we present direct evidence in support of this using the rabbit ischemic hindlimb model injected with adenovirus encoding VEGF165. Immunohistology indicated an activation of endothelial cell cycling and proliferation 2–3 days after VEGF delivery that coincided closely with transient VEGF expression. Ki-67-positive endothelial nuclei were evident at high levels in capillaries and large vessels in muscles from treated animals. Angiography indicated increased density of both large and small vessels in Ad-VEGF-treated muscle at 1 week, but no significant differences thereafter. The early burst of endothelial proliferation was accompanied by increased nuclear fragmentation and condensation in VEGF-treated muscles, suggesting coincident apoptosis. No further endothelial cell proliferation took place after 1 week although there was still evidence of apoptosis. The results suggest that angiogenesis is confined to the short period of VEGF expression produced by adenovirus and early gains in collateralization rapidly regress to control levels when VEGF production ceases.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  1. Schainfeld DO, Isner JM . Critical limb ischemia: nothing to give at the office. Annal Int Med 1999; 130: 442–444.

    Article  CAS  Google Scholar 

  2. Isner JM, Asahara T . Angiogenesis and vasculogenesis as therapeutic strategies for postnatal vascularization. J Clin Invest 1999; 103: 1231–1236.

    Article  CAS  Google Scholar 

  3. Webster KA . Therapeutic angiogenesis: a case for targeted, regulated gene delivery. Crit Rev Eukaryot Gene Expr 2000; 10: 113–125.

    Article  CAS  Google Scholar 

  4. Webster KA . Therapeutic angiogenesis: a complex problem requiring a sophisticated approach. Cardiovasc Toxicol 2003; 3: 283–298.

    Article  CAS  Google Scholar 

  5. Shyu K-G et al. Direct intramuscular injection of plasmid DNA encoding angiopoietin-1 but not angiopoietin-2 augments revascularization in rabbot ischemic hindlimb. Circulation 1998; 98: 2081–2087.

    Article  CAS  Google Scholar 

  6. Nikol S et al. Vascular endothelial growth factor (VEGF (165)) and its influence on angiogenesis versus arteriogenesis in different vascular beds. J Endovasc Ther 2002; 9: 842–845.

    PubMed  Google Scholar 

  7. Kutryk MJ, Stewart DJ . Angiogenesis of the heart. Microsc Res Tech 2003; 60: 138–158.

    Article  Google Scholar 

  8. Mohler III ER et al. Adenoviral-mediated gene transfer of vascular endothelial growth factor in critical limb ischemia: safety results from a phase I trial. Vasc Med 2003; 8: 9–13.

    Article  Google Scholar 

  9. Rajagopalan S et al. Adenovirus-mediated gene transfer of VEGF(121) improves lower-extremity endothelial function and flow reserve. Circulation 2001; 104: 753–755.

    Article  CAS  Google Scholar 

  10. Rajagopalan S et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003; 108: 1933–1938.

    Article  CAS  Google Scholar 

  11. Vajanto I et al. Evaluation of angiogenesis and side effects in ischemic rabbit hindlimbs after intramuscular injection of adenoviral vectors encoding VEGF and LacZ. J Gene Med 2002; 4: 371–380.

    Article  CAS  Google Scholar 

  12. Hershey JC et al. Vascular endothelial growth factor stimulates angiogenesis without improving collateral blood flow following hindlimb ischemia in rabbits. Heart Vessels 2003; 18: 142–149.

    Article  Google Scholar 

  13. Murphy BJ et al. Activation of metallothionine gene expression by hypoxia involves metal response elements and metal transcription factor-1. Cancer Res 1999; 59: 1315–1322.

    CAS  PubMed  Google Scholar 

  14. Asahara T, Bauters C, Zheng LP, Isner JM . Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis. Circulation 1995; 92: II365–II371.

    Article  CAS  Google Scholar 

  15. Perrin LA et al. Increased revascularization efficacy after administration of an adenovirus encoding VEGF121. Gene Therapy 2004; 11: 512–521.

    Article  CAS  Google Scholar 

  16. Hoefer IE et al. Time course of arteriogenesis following femoral artery occlusion in the rabbit. Cardiovasc Res 2001; 49: 609–617.

    Article  CAS  Google Scholar 

  17. Schumacher B, Pecher P, von Specht BU, Stegmann T . Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation 1998; 97: 645–650.

    Article  CAS  Google Scholar 

  18. Gowdak LH et al. Induction of angiogenesis by cationic lipid-mediated VEGF165 gene transfer in the rabbit ischemic hindlimb model. J Vasc Surg 2000; 32: 343–352.

    Article  CAS  Google Scholar 

  19. Mack CA et al. Salvage angiogenesis induced by adenovirus-mediated gene transfer of vascular endothelial growth factor protects against ischemic vascular occlusion. J Vasc Surg 1998; 27: 699–709.

    Article  CAS  Google Scholar 

  20. Dor Y et al. Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J 2002; 21: 1939–1947.

    Article  CAS  Google Scholar 

  21. Ferrara N . Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002; 29 (Suppl 16): 10–14.

    Article  CAS  Google Scholar 

  22. Webster KA . Molecular switches for regulating therapeutic genes. Gene Therapy 1999; 6: 951–953.

    Article  CAS  Google Scholar 

  23. Chang DS et al. Adeno-associated viral vector-mediated gene transfer of VEGF normalizes skeletal muscle oxygen tension and induces arteriogenesis in ischemic rat hindlimb. Mol Ther 2003; 7: 44–51.

    Article  CAS  Google Scholar 

  24. Prentice H et al. Regulated expression of a foreign gene targeted to the ischemic myocardium. Card Res 1997; 35: 567–574.

    Article  CAS  Google Scholar 

  25. Muhlhauser J et al. VEGF165 expressed by a replication-deficient recombinant adenovirus vector induces angiogenesis in vivo. Circ Res 1995; 77: 1077–1086.

    Article  CAS  Google Scholar 

  26. Gaetano C et al. Transcriptionally active drugs improve adenovirus vector performance in vitro and in vivo. Gene Therapy 2000; 7: 1624–1630.

    Article  CAS  Google Scholar 

  27. Sadasivan C et al. Quantification of stent efficacy in modulating angiographic dye washout from cerebral aneurysms. Am J Neuroradiol 2002; 23: 1214–1221.

    PubMed  Google Scholar 

  28. Lieber BB et al. The hemodynamics of angiogenesis: angiographic study using the rabbit hind limb ischemia model. ASME Proceedings 2003. http://www.asme.org/divisions/bed/events/summer03.html.

  29. Webster KA . et al. Hypoxia-activated apoptosis of cardiac myocytes requires reoxygenation or a pH shift and is independent of p53. J Clin Invest 1999; 104: 239–252.

    Article  CAS  Google Scholar 

  30. Dougherty CJ et al. Activation of c-Jun N-terminal kinase promotes survival of cardiac myocytes after oxidative stress. Biochem J 2002; 362: 561–571.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by grant #HL69812 (KAW) from the National Institutes of Health. We acknowledge Dr Andrea Gambotto, of the Vector Core Facility, Molecular Medicine Institute, University of Pittsburgh, and the Cell Morphology Core, Gene Therapy Program, of the University of Pennsylvania School of Medicine for assistance with large-scale adenoviral preparation and immunostaining of muscle sections, respectively. We also thank Dr MC Capogrossi for generously providing Ad-CMV-VEGF 165.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gounis, M., Spiga, MG., Graham, R. et al. Angiogenesis is confined to the transient period of VEGF expression that follows adenoviral gene delivery to ischemic muscle. Gene Ther 12, 762–771 (2005). https://doi.org/10.1038/sj.gt.3302481

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3302481

Keywords

This article is cited by

Search

Quick links